Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.

Clicks: 206
ID: 108593
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
This paper presents the synthesis and glucokinase activity of novel hydrazone derivatives. The 2-(4-cyclopropylsulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-acetamide derivatives 5a-5h presented the in vitro glucokinase activities and in vivo blood glucose-lowering effects in mice. Particularly, 5h showed an oral hypoglycemic effect in rats at 1 mg/kg. These hydrazone derivatives are a potential new class of glucokinase activators for the treatment of type 2 diabetes.
Reference Key
sugama2020designbioorganic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sugama, Hiroshi;Matsudaira, Tetsuji;Yanagisawa, Hideyuki;Ohashi, Rikiya;Nawano, Masao;Yasuda, Kosuke;Takayama, Hiromitsu;
Journal Bioorganic & medicinal chemistry letters
Year 2020
DOI
S0960-894X(20)30354-1
URL
Keywords
type 2 diabetes hydrazone derivatives glucokinase activators herg inhibition

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.